Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke. Issue 2 (27th November 2020)

• Record Type: Journal Article
• Authors: Wu, Simiao; Mair, Grant; Cohen, Geoff; Morris, Zoe; von Heijne, Anders; Bradey, Nick; Cala, Lesley; Peeters, Andre; Farrall, Andrew J; Adami, Alessandro; Potter, Gillian; Liu, Ming; Lindley, Richard I; Sandercock, Peter A G; Wardlaw, Joanna M
• Is Part Of: Stroke and vascular neurology. Volume 6:Issue 2(2021)
• Page Start: 238
• Page End: 243
• Publication Date: 2020-11-27
• Subjects: stroke -- thrombolysis -- complication; Cerebrovascular disease -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.81005
• DOI: 10.1136/svn-2020-000569
• Languages: English
• ISSNs: 2059-8688

Abstract

Abstract : Background: Alteplase improves functional outcomes of patients with acute ischaemic stroke, but its effects on symptomatic infarct swelling, an adverse complication of stroke and the influence of CT hyperdense artery sign (HAS) are unclear. This substudy of the Third International Stroke Trial aimed to investigate the association between HAS and symptomatic infarct swelling and effect of intravenous alteplase on this association. Methods: We included stroke patients whose prerandomisation scan was non-contrast CT. Raters, masked to clinical information, assessed baseline (prerandomisation) and follow-up (24–48 hours postrandomisation) CT scans for HAS, defined as an intracranial artery appearing denser than contralateral arteries. Symptomatic infarct swelling was defined as clinically significant neurological deterioration ≤7 days after stroke with radiological evidence of midline shift, effacement of basal cisterns or uncal herniation. Results: Among 2961 patients, HAS presence at baseline was associated with higher risk of symptomatic infarct swelling (OR 2.21; 95% CI 1.42 to 3.44). Alteplase increased the risk of swelling (OR 1.69; 95% CI 1.11 to 2.57), with no difference between patients with and those without baseline HAS (p=0.49). In patients with baseline HAS, alteplase reduced the proportion with HAS at follow-up (OR 0.67; 95% CI 0.50 to 0.91), where HAS disappearance was associated with reduced risk of swelling (OR 0.25, 95% CI 0.14 to 0.47). Conclusion: Although alteplase was associated with increased risk of symptomatic infarct swelling in patients with or without baseline HAS, it was also associated with accelerated clearance of HAS, which in return reduced swelling, providing further mechanistic insights to underpin the benefits of alteplase.